TL;DR
- Ebola vaccine for Bundibugyo strain delayed.
- Human trials may take 6-9 months.
- Merck’s Ervebo vaccine under review.
- Limited protection shown in animal studies.
- Health officials revert to basic containment strategies.
In a world where we’re all praying for a miracle cure, the news about the Ebola vaccine for the Bundibugyo strain is anything but uplifting. The World Health Organization (WHO) has dropped a bombshell: it’s likely going to take months before we see any human trials for this vaccine. And let’s be real, there’s no guarantee it will even work. Talk about a nail-biter!
Currently, there are no approved vaccines for this particular strain of the Ebola virus, which is causing quite the stir in the Democratic Republic of Congo and Uganda. According to Dr. Vasee Moorthy, the head honcho of WHO’s research and development blueprint, there are two potential candidates in the pipeline. However, neither is ready to jump into human testing just yet. The more promising option could take a whopping six to nine months before we see enough doses ready for trials. Meanwhile, the other candidate might show up in two to three months, but it’s still waiting for some solid results from animal studies. “It will depend on the animal data as to whether that is considered a promising candidate vaccine for Bundibugyo,” Dr. Moorthy explained. Fingers crossed, right?
As the clock ticks, health officials are scrambling for alternatives. Enter Merck’s Ebola vaccine, Ervebo, which targets the Zaire strain—the most common and deadly type of Ebola. There’s some buzz from animal studies suggesting that Ervebo might offer a smidgen of protection against the Bundibugyo virus. But don’t get too excited; experts are quick to point out that the existing data is pretty limited. “It is not a vaccine for Bundibugyo,” Moorthy clarified. A review is currently underway to see if Ervebo could help mitigate the current outbreak, but it’s still a long shot.
Let’s not forget about the science behind this. A 2011 study published in the Journal of Infectious Diseases found that an early version of Ervebo offered limited protection against the Bundibugyo virus in macaques. Out of four vaccinated animals, three survived exposure to Bundibugyo, while only one out of three unvaccinated ones made it. But hold your applause—those vaccinated macaques still showed symptoms. So, while it sounds promising, the protection rate might be closer to 50%, according to Tom Geisbert, an Ebola expert for the WHO. “It’s a coin flip,” he said. And honestly, who wants to play that game?
Until now, global health officials had found little need for a Bundibugyo vaccine, as previous outbreaks were small and relatively easy to contain. But with a mortality rate of around 25% to 40%, it’s clear that this virus is no joke. Dr. Geeta Sood from Johns Hopkins Bayview Medical Center pointed out that the Bundibugyo virus is less lethal than other strains, which average around 50% to 60%. But without a vaccine, public health officials are going back to basics—contact tracing, safe isolation of patients, and infection prevention and control. It’s a tough reality, but it’s the best we can do for now.
In a world that’s constantly evolving, the race for an effective Ebola vaccine is a stark reminder of the challenges we face in global health. As we wait for the next steps, let’s keep our fingers crossed that science will come through for us—because right now, hope is hanging by a thread.
https://www.youtube.com/nbcnews